Therapeutic Response

CD20 + status confers therapeutic sensitivity to Rituximab in patients with Follicular Lymphoma.

Statements

Source and description
Rituxan (rituximab) [product monograph]. HC. Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.